IBEX LTD (IBEX) Stock Fundamental Analysis

NASDAQ:IBEX • BMG4690M1010

29.55 USD
0 (0%)
At close: Feb 20, 2026
29.55 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall IBEX gets a fundamental rating of 7 out of 10. We evaluated IBEX against 87 industry peers in the IT Services industry. Both the health and profitability get an excellent rating, making IBEX a very profitable company, without any liquidiy or solvency issues. IBEX is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make IBEX a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year IBEX was profitable.
  • IBEX had a positive operating cash flow in the past year.
  • IBEX had positive earnings in each of the past 5 years.
  • IBEX had a positive operating cash flow in each of the past 5 years.
IBEX Yearly Net Income VS EBIT VS OCF VS FCFIBEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

1.2 Ratios

  • IBEX's Return On Assets of 14.58% is amongst the best of the industry. IBEX outperforms 93.10% of its industry peers.
  • IBEX has a better Return On Equity (28.81%) than 89.66% of its industry peers.
  • The Return On Invested Capital of IBEX (21.63%) is better than 95.40% of its industry peers.
Industry RankSector Rank
ROA 14.58%
ROE 28.81%
ROIC 21.63%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBEX Yearly ROA, ROE, ROICIBEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

1.3 Margins

  • The Profit Margin of IBEX (7.14%) is better than 73.56% of its industry peers.
  • IBEX's Profit Margin has improved in the last couple of years.
  • The Operating Margin of IBEX (9.18%) is better than 66.67% of its industry peers.
  • IBEX's Operating Margin has improved in the last couple of years.
  • The Gross Margin of IBEX (30.62%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of IBEX has remained more or less at the same level.
Industry RankSector Rank
OM 9.18%
PM (TTM) 7.14%
GM 30.62%
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
IBEX Yearly Profit, Operating, Gross MarginsIBEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IBEX is creating value.
  • IBEX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IBEX Yearly Shares OutstandingIBEX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IBEX Yearly Total Debt VS Total AssetsIBEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • IBEX has an Altman-Z score of 4.83. This indicates that IBEX is financially healthy and has little risk of bankruptcy at the moment.
  • IBEX's Altman-Z score of 4.83 is amongst the best of the industry. IBEX outperforms 80.46% of its industry peers.
  • IBEX has a debt to FCF ratio of 0.05. This is a very positive value and a sign of high solvency as it would only need 0.05 years to pay back of all of its debts.
  • IBEX's Debt to FCF ratio of 0.05 is amongst the best of the industry. IBEX outperforms 91.95% of its industry peers.
  • IBEX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.01, IBEX belongs to the top of the industry, outperforming 83.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.05
Altman-Z 4.83
ROIC/WACC2.2
WACC9.82%
IBEX Yearly LT Debt VS Equity VS FCFIBEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • IBEX has a Current Ratio of 1.82. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.82, IBEX is in line with its industry, outperforming 55.17% of the companies in the same industry.
  • IBEX has a Quick Ratio of 1.82. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.82, IBEX is in line with its industry, outperforming 55.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.82
IBEX Yearly Current Assets VS Current LiabilitesIBEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.77% over the past year.
  • Measured over the past years, IBEX shows a very strong growth in Earnings Per Share. The EPS has been growing by 41.04% on average per year.
  • Looking at the last year, IBEX shows a quite strong growth in Revenue. The Revenue has grown by 9.77% in the last year.
  • The Revenue has been growing slightly by 6.62% on average over the past years.
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
Revenue 1Y (TTM)9.77%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.72% on average over the next years. This is quite good.
  • IBEX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.19% yearly.
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.81%
Revenue Next 2Y9.19%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBEX Yearly Revenue VS EstimatesIBEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
IBEX Yearly EPS VS EstimatesIBEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 8.54, the valuation of IBEX can be described as reasonable.
  • 88.51% of the companies in the same industry are more expensive than IBEX, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 26.99. IBEX is valued rather cheaply when compared to this.
  • IBEX is valuated reasonably with a Price/Forward Earnings ratio of 8.16.
  • Based on the Price/Forward Earnings ratio, IBEX is valued cheaply inside the industry as 90.80% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, IBEX is valued rather cheaply.
Industry RankSector Rank
PE 8.54
Fwd PE 8.16
IBEX Price Earnings VS Forward Price EarningsIBEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • IBEX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IBEX is cheaper than 90.80% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of IBEX indicates a somewhat cheap valuation: IBEX is cheaper than 71.26% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 12.7
EV/EBITDA 5.32
IBEX Per share dataIBEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • IBEX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • IBEX has a very decent profitability rating, which may justify a higher PE ratio.
  • IBEX's earnings are expected to grow with 13.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.37
PEG (5Y)0.21
EPS Next 2Y13.72%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IBEX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBEX LTD

NASDAQ:IBEX (2/20/2026, 8:00:01 PM)

After market: 29.55 0 (0%)

29.55

0 (0%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners94.08%
Inst Owner Change-0.03%
Ins Owners2.8%
Ins Owner Change14.36%
Market Cap396.27M
Revenue(TTM)558.27M
Net Income(TTM)41.38M
Analysts45.71
Price Target41.82 (41.52%)
Short Float %0.8%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.95%
Min EPS beat(2)20.05%
Max EPS beat(2)21.85%
EPS beat(4)4
Avg EPS beat(4)16.83%
Min EPS beat(4)10.89%
Max EPS beat(4)21.85%
EPS beat(8)7
Avg EPS beat(8)12.58%
EPS beat(12)10
Avg EPS beat(12)14.59%
EPS beat(16)12
Avg EPS beat(16)13.3%
Revenue beat(2)2
Avg Revenue beat(2)5.51%
Min Revenue beat(2)2.5%
Max Revenue beat(2)8.52%
Revenue beat(4)4
Avg Revenue beat(4)4.65%
Min Revenue beat(4)2.45%
Max Revenue beat(4)8.52%
Revenue beat(8)5
Avg Revenue beat(8)1.79%
Revenue beat(12)5
Avg Revenue beat(12)-0.35%
Revenue beat(16)7
Avg Revenue beat(16)-0.06%
PT rev (1m)0%
PT rev (3m)6.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.48%
EPS NY rev (1m)0%
EPS NY rev (3m)5.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.82%
Valuation
Industry RankSector Rank
PE 8.54
Fwd PE 8.16
P/S 0.68
P/FCF 12.7
P/OCF 7.4
P/B 2.76
P/tB 3.01
EV/EBITDA 5.32
EPS(TTM)3.46
EY11.71%
EPS(NY)3.62
Fwd EY12.25%
FCF(TTM)2.33
FCFY7.87%
OCF(TTM)4
OCFY13.52%
SpS43.23
BVpS10.71
TBVpS9.83
PEG (NY)0.37
PEG (5Y)0.21
Graham Number28.88
Profitability
Industry RankSector Rank
ROA 14.58%
ROE 28.81%
ROCE 26.64%
ROIC 21.63%
ROICexc 24.4%
ROICexgc 26.15%
OM 9.18%
PM (TTM) 7.14%
GM 30.62%
FCFM 5.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.05
Debt/EBITDA 0.01
Cap/Depr 129.83%
Cap/Sales 3.86%
Interest Coverage 31.53
Cash Conversion 76.01%
Profit Quality 75.39%
Current Ratio 1.82
Quick Ratio 1.82
Altman-Z 4.83
F-Score8
WACC9.82%
ROIC/WACC2.2
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.77%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%
Revenue Next Year12.81%
Revenue Next 2Y9.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.48%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year68.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.26%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y19.11%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%

IBEX LTD / IBEX FAQ

Can you provide the ChartMill fundamental rating for IBEX LTD?

ChartMill assigns a fundamental rating of 7 / 10 to IBEX.


What is the valuation status for IBEX stock?

ChartMill assigns a valuation rating of 8 / 10 to IBEX LTD (IBEX). This can be considered as Undervalued.


What is the profitability of IBEX stock?

IBEX LTD (IBEX) has a profitability rating of 7 / 10.


What is the valuation of IBEX LTD based on its PE and PB ratios?

The Price/Earnings (PE) ratio for IBEX LTD (IBEX) is 8.54 and the Price/Book (PB) ratio is 2.76.


Is the dividend of IBEX LTD sustainable?

The dividend rating of IBEX LTD (IBEX) is 0 / 10 and the dividend payout ratio is 0%.